Urimax%25252525252525252525252525252525252525252525252525252525252525252525252525252520%25252525252525252525252525252525252525252525252525252525252525252525252525252528tamsulosin%25252525252525252525252525252525252525252525252525252525252525252525252525252529

# Urimax (Tamsulosin) ## Overview Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially blocks alpha-1A receptors in the prostate and bladder neck, promoting smooth muscle relaxation and improving urinary flow. ## Primary Indications * Treatment of signs and symptoms of benign prostatic hyperplasia (BPH). * Off-label: Medical expulsive therapy for ureteral calculi. ## Adult Dosing * **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day. * **Maximum Dose:** 0.8 mg daily if no response after 2–4 weeks at 0.4 mg. ## Pediatric Dosing * **Established:** Not FDA-approved for pediatric use. * **Off-label/Specialist use:** Sometimes used in pediatric urology for dysfunctional voiding or neurogenic bladder under specialist supervision; dosing is highly variable based on institutional protocol (typically significantly lower than adult doses). **Consult pediatric urology guidelines.** ## Dose Adjustments * **Renal Impairment:** No dose adjustment required. * **Hepatic Impairment:** Use with caution in severe impairment; no formal dosing guidelines exist, but monitor for systemic hypotension. * **CYP3A4/2D6 Inhibitors:** Avoid or exercise extreme caution when co-administering with potent inhibitors. ## Contraindications * Hypersensitivity to tamsulosin or any component of the formulation. * History of angioedema. ## Adverse Effects * **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis, asthenia. * **Serious:** Orthostatic hypotension (risk highest with first dose), syncope, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery. ## Key Drug Interactions * **Potent CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May significantly increase tamsulosin exposure. * **Other Alpha-Blockers/Antihypertensives:** Increased risk of severe hypotension when combined with PDE5 inhibitors (e.g., sildenafil) or other antihypertensives. * **CYP2D6 Inhibitors (e.g., paroxetine):** May moderately increase tamsulosin exposure. ## Monitoring * Monitor for orthostatic vital signs, especially during titration. * Monitor urinary symptom improvement (e.g., IPSS scores). * Assess for PSA changes if screening for prostate cancer. * Advise patients to inform ophthalmologists of tamsulosin use before scheduled cataract surgery. ## Clinical Pearls * **Administration:** Must be taken 30 minutes after the same meal each day to ensure consistent bioavailability; taking it on an empty stomach increases the risk of hypotension. * **IFIS:** Tamsulosin is the most frequent cause of IFIS; surgery should be postponed or managed by ophthalmologists aware of the history. * **Efficacy:** Maximal benefits on urinary flow are typically seen within 1–2 weeks. *** *Disclaimer: This information is for educational purposes only. Clinical practices vary by institution and patient-specific factors. Always verify current prescribing information through local pharmacy databases, clinical guidelines, or the manufacturer’s package insert before prescribing or administering medication.*